Wire · opportunities
Global Cell and Gene Therapy CDMO Selects Valkit.ai
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
A global cell and gene therapy contract development and manufacturing organization (CDMO) has selected Valkit.ai's AI-powered digital validation platform to replace its first-generation system across its worldwide operations, enhancing Commissioning & Qualification, Computer System Validation, and Computer Software Assurance processes with AI-native architecture.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a new standard in validation technology as Valkit.ai shifts compliance from manual workflows to AI-driven automation. This leap lets you cut validation time drastically and boost documentation accuracy, opening faster regulatory readiness for your therapy manufacturing.
◆ Coverage
1 source · 21 Sep 2026
◆ Related on Wire
◆ Topics